Skip to main content

Table 7 Antimicrobial sensitivity pattern of the hemolytic toxin harboring E. coli isolates (hly+cnf1+clbA+clbQ+) versus the non-hemolytic non-toxin harboring E. coli isolates (hly−cnf1−clbA−clbQ−) against 11 antimicrobial agents

From: Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor-1 (Cnf 1) in Escherichia coli: experimental and bioinformatics analyses

Isolate code

Resistance profile

Genetic pattern

SXT 25

CRO 30

AMC 30

CAZ 30

LEVO 30

CIP 5

OFL 5

GAT 5

F 300

NA 30

DO 30

cnf-1

clb A

clb Q

ATCC 25299

S

S

S

S

S

S

S

S

S

S

S

+

−

−

Hemolytic toxin harboring E. coli isolates (hly+cnf1+clbA+clbQ+)

 4β

R

R

I

R

S

S

S

S

S

S

S

+

+

+

 5β

R

R

R

R

R

R

R

R

S

R

R

+

−

−

 6β

S

S

S

S

S

S

S

S

S

S

S

+

+

+

 10β

R

S

R

S

R

R

R

R

S

R

R

+

+

+

 27β

S

R

S

I

S

S

S

S

S

S

S

+

+

+

 28β

R

S

S

R

S

S

S

S

S

R

R

+

+

+

 29β

S

S

S

S

S

S

S

S

S

S

S

+

+

+

 70β

S

S

S

R

S

S

S

S

S

S

S

+

+

+

 99β

R

S

S

I

S

S

S

S

S

S

S

−

+

+

 114β

R

R

S

S

S

S

S

S

S

S

S

+

+

+

 Percent sensitive

40%

60%

70%

40%

80%

80%

80%

80%

100%

70%

70%

   

 Percent intermediate

0

0

10%

20%

0

0

0

0

0

0

0

Non hemolytic non-toxin harboring E. coli isolates (hly−cnf1−clbA−clbQ−)

 20

R

S

I

R

S

S

S

S

S

S

R

−

−

−

 45

R

R

R

R

I

I

S

S

S

S

R

−

−

−

 52

R

R

R

R

R

R

I

I

S

S

R

−

−

−

 58

R

R

R

R

R

R

R

R

S

S

R

−

−

−

 63

R

R

R

R

R

R

R

R

S

S

R

−

−

−

 67

R

R

R

R

R

R

R

R

S

I

R

−

−

−

 69

R

R

R

R

R

R

R

R

S

I

R

−

−

−

 74

R

R

R

R

R

R

R

R

S

R

R

−

−

−

 93

R

S

S

R

S

S

S

S

S

S

S

−

−

−

 120

R

R

R

R

R

R

R

R

R

I

R

−

−

−

 Percent resistance

100%

80%

80%

100%

70%

70%

60%

60%

10%

10%

100%

 

 Percent intermediate

0%

0%

10%

0%

10%

10%

10%

10%

0%

30%

0%

  1. SXT trimethoprim/sulfamethoxazole 1.25/30 µg, CRO ceftriaxone 30 µg, AMC amoxicillin/clavulanic acid 20/10 µg, CAZ ceftazidime 30 µg, LEVO levofloxacin 30 µg, CIP ciprofloxacin 5 µg, OFL ofloxacin 5 µg, GAT gatifloxacin 5 µg, F nitrofurantoin 300 µg, NA nalidixic acid 30 µg, DO doxycycline 30 µg